Home › Avoidant Restrictive Food Intake Disorder › NCT06898177

Development and Testing of a Mobile App to Scale Delivery of Cognitive-behavioral Therapy for Avoidant/Restrictive Food Intake Disorder

Who can join

Ages 18 to 55 · All sexes

Inclusion Criteria:

1. Current avoidant/restrictive food intake disorder based on DSM-5 criteria
2. Must not have completed face-to-face CBT-AR at the Eating Disorders Clinical and Research Program at Massachusetts General Hospital
3. Ability to speak, write, and understand English
4. Residence in the United States
5. Access to an internet-connected smartphone device

Exclusion Criteria:

1. Underweight status (i.e., BMI \< 18.5 kg/m2)
2. Complete lack of oral intake or dependence on supplemental feeding
3. Feeding or eating disorder other than ARFID
4. Any comorbid clinically significant disorder that would require attention beyond the study treatment

6\. Medical instability requiring inpatient care according to the American Psychiatric Association 2023 treatment guidelines for eating disorders 7. Medical history of intellectual disability 8. Illiteracy

About the study

Avoidant/restrictive food intake disorder (ARFID) is a serious and impairing eating disorder - occurring in up to 4% of adults - for which most individuals do not have access to treatment. The proposed study aims to develop and test a mobile app to scale delivery of cognitive-behavioral therapy for ARFID. Knowledge gained will contribute to the development of a clinically accessible, scalable, inexpensive treatment for ARFID, a highly impairing disorder for which there are significant barriers to care access.

What is being tested

• mCBT-AR (behavioral)

Sponsor: Massachusetts General Hospital · Participants: 60 · Started: Apr 13, 2026

Contact the study team

• Paraskevi Kambanis, PhD · Phone: 617-724-0799

Official record on ClinicalTrials.gov — NCT06898177

Locations in the U.S.

Conditions

• Avoidant Restrictive Food Intake Disorder

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.